Schering-Plough
This article was originally published in The Tan Sheet
Executive Summary
Company's non-sedating antihistamine Claritin (loratadine) has been granted six months of pediatric exclusivity, Schering announces Aug. 16. The patent for Claritin was set to expire in June 2002, the company says. The studies Schering submitted in its request for additional marketing exclusivity also are part of supplemental NDAs for Claritin syrup to expand the indications to include children two to five years old. Claritin was discussed as an appropriate switch candidate at an FDA public meeting in June (1"The Tan Sheet" July 3, p. 3)
You may also be interested in...
Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands